[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
May 13, 2009

Antioxidant Supplementation and Cancer Prevention

JAMA. 2009;301(18):1877-1879. doi:10.1001/jama.2009.628

To the Editor: In his Editorial about the null results of the SELECT and Physicians' Health Study II clinical trials, Dr Gann1 raised the important issue of preclinical science in chemopreventive agent development. A critical component of the preclinical development of any candidate cancer chemopreventive agent is the demonstration of its anticarcinogenic efficacy in biologically relevant animal models. Findings of significant chemopreventive activity in such models are key elements of the rational selection of agents for subsequent evaluation in clinical prevention trials.

First Page Preview View Large
First page PDF preview
First page PDF preview
×